公开(公告)号：US20240261367A1

公开(公告)日：2024-08-08

申请号：US18554675

申请日：2022-04-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： TAO WANG

IPC: A61K38/12 ,  A61K47/54 ,  A61K47/60

CPC classification number: A61K38/12 ,  A61K47/543 ,  A61K47/545 ,  A61K47/60

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

公开(公告)号：US20240218022A1

公开(公告)日：2024-07-04

申请号：US18509844

申请日：2023-11-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： JENNIFER X. QIAO ,  YUNHUI ZHANG ,  KENNETH M. BOY ,  MICHAEL A. POSS

IPC: C07K7/64

CPC classification number: C07K7/64

Abstract: This invention relates to novel anti-VISTA macrocyclic peptides and their related analogs with appended pharmacokinetic-enhancing tails (PKEs) with general structure of formula (I), which can be used as VISTA inhibitors.

公开(公告)号：US12012374B2

公开(公告)日：2024-06-18

申请号：US17610548

申请日：2020-05-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Muthoni G. Kamau ,  Brian E. Fink

IPC: C07D207/12 ,  C07C317/22 ,  C07D401/06 ,  C07D403/06 ,  C07D407/06 ,  C07D409/06 ,  C07D417/06

CPC classification number: C07C317/22 ,  C07D207/12 ,  C07D401/06 ,  C07D403/06 ,  C07D407/06 ,  C07D409/06 ,  C07D417/06

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20240190829A1

公开(公告)日：2024-06-13

申请号：US18524426

申请日：2023-11-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

CPC classification number: C07D249/04 ,  A61K31/501 ,  A61P25/16 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US11981734B2

公开(公告)日：2024-05-14

申请号：US17668807

申请日：2022-02-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Natalie Bezman ,  Alan J. Korman ,  Shrikant Deshpande ,  Amy D. Jhatakia ,  Richard Y. Huang ,  Guodong Chen ,  Ginger C. Rakestraw ,  Karla Ann Henning ,  Vangipuram S. Rangan ,  Christine Bee ,  Xiang Shao

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K1/22 ,  C12N5/071 ,  C12N15/85 ,  C12P21/00 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K47/6849 ,  A61P35/00 ,  C07K1/22 ,  C12N5/0682 ,  C12N15/85 ,  C12P21/005 ,  G01N33/68 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02 ,  C12N2800/107

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

公开(公告)号：US20240132608A1

公开(公告)日：2024-04-25

申请号：US18500831

申请日：2023-11-01

Applicant: Bristol-Myers Squibb Company

Inventor： Josephine M. CARDARELLI ,  Daniel E. LOPES de MENEZES ,  Paul D. PONATH ,  Bingliang CHEN ,  Chin PAN

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61K39/39533 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77

Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.

公开(公告)号：US11964973B2

公开(公告)日：2024-04-23

申请号：US17130022

申请日：2020-12-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert G. Gentles ,  Upender Velaparthi ,  Min Ding ,  Richard E. Olson ,  Scott W. Martin ,  Saumya Roy ,  Prasada Rao Jalagam ,  Jayakumar Sankara Warrier ,  Louis S. Chupak ,  Denise Christine Grunenfelder

IPC: C07D471/04 ,  C07D401/04

CPC classification number: C07D471/04 ,  C07D401/04

Abstract: Disclosed are compounds of Formula (I):




or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20240124589A1

公开(公告)日：2024-04-18

申请号：US18473858

申请日：2023-09-25

Applicant: Bristol-Myers Squibb Company

Inventor： Marina TSCHAIKA

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61K2039/507

Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

公开(公告)号：US20240124489A1

公开(公告)日：2024-04-18

申请号：US17766198

申请日：2020-09-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Sreekantha Ratna Kumar ,  Lazman Pasunoori ,  Subramanya Hegde ,  Anupama Kandhi ,  Durga Buchi Paju Barre ,  Alaric J. Dyckman

IPC: C07D513/04 ,  C07D519/00

CPC classification number: C07D513/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20240124417A1

公开(公告)日：2024-04-18

申请号：US17766483

申请日：2020-10-01

Applicant: Bristol-Myers Squibb Company

Inventor： Kap-Sun YEUNG ,  Denis R. ST. LAURENT ,  Li-Qiang SUN ,  Zhiwei YIN ,  Katharine A. GRANT-YOUNG ,  Paul Michael SCOLA

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.